EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...
SWX: ROG
Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received market approval from...
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...
CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026
China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...
Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO
Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...
Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...
Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials
The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...
Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...
Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...
Roche’s Alecensa Achieves Milestone in Adjuvant Therapy Trial for Early-Stage NSCLC
Switzerland-based pharmaceutical giant Roche (SWX: ROG) has released an update from an interim analysis of...
Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA
Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...
MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment
The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...